☆ 4.4 Article

Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases

NEUROENDOCRINOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms

Andreas Venizelos et al.

Summary: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are a rare and understudied type of tumors, with a very poor prognosis. Molecular analysis of 181 HG GEP-NEN patients revealed unique genetic alterations and copy number changes in different subgroups of tumors, indicating potential personalized treatment options. Limited similarities were found with small-cell lung cancer (SCLC), suggesting the need for subtype-specific therapeutic approaches.

ENDOCRINE-RELATED CANCER (2022)

Add to Collection

Review Gastroenterology & Hepatology

Advances in medical treatment for pancreatic neuroendocrine neoplasms

Yuan-Liang Li et al.

Summary: PanNENs are rare neoplasms with strong heterogeneity. There are various systemic treatment options available for advanced PanNENs patients. Combining drugs with different mechanisms of action provides new possibilities for clinical treatments.

WORLD JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Surgery

Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling

Catherine G. Tran et al.

Summary: Metastatic pancreatic neuroendocrine tumors have lower expression of somatostatin compared to primary tumors, and knocking down somatostatin can increase cell growth and metabolic activity. This phenomenon may be attributed to increased activation of Akt.

SURGERY (2021)

Add to Collection

Review Oncology

Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives

Noemi Simeone et al.

Summary: Epithelioid sarcoma is a rare and aggressive soft tissue sarcoma marked by SMARCB1/INI1 deficiency. Tazemetostat, an oral inhibitor of EZH2, has shown clinical activity in ES patients with INI1-negative tumors, but there is still a need for further research to identify predictors of response and potential combination therapies.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)

Simon Leonhard April-Monn et al.

Summary: Pancreatic neuroendocrine neoplasms are driven by epigenetic factors, with high EZH2 expression associated with higher tumor grade, distant metastases, and shorter disease-free survival. Inhibition of EZH2 reduces cell viability and proliferation in PanNEN cell lines and patient-derived tumoroids, as well as decreases tumor burden in mouse models. Targeting EZH2 could be a valuable epigenetic treatment option for patients with PanNEN.

CANCERS (2021)

Add to Collection

Review Oncology

Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?

Satya Das et al.

Summary: The purpose of the review is to explore global epidemiologic trends of gastroenteropancreatic neuroendocrine tumors (NETs), looking at differences in incidence, prevalence, distribution, and overall survival between different regions. GEP NET incidence rates are rising steadily in North America, Asia, and Europe, with differences in distribution of NETs among regions. Improved overall survival for GEP NET patients is also observed over time.

CURRENT ONCOLOGY REPORTS (2021)

Add to Collection

Review Oncology

Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors

Satya Das et al.

Summary: Research on GEP NET in recent years has shown that the development of new drugs such as PRRT and RTKIs holds great promise and may improve treatment outcomes for patients. Immunotherapy is also seen as a treatment direction, and some new approaches may be realized for clinical use in the future, further improving the survival prospects of patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

Fumi Higuchi et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: A SEER database analysis.

Mohamad Bassam Sonbol et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Cell Biology

EMT, MET, Plasticity, and Tumor Metastasis

Basil Bakir et al.

TRENDS IN CELL BIOLOGY (2020)

Add to Collection

Article Oncology

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Mrinal Gounder et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Genetics & Heredity

Resolving genetic heterogeneity in cancer

Samra Turajlic et al.

NATURE REVIEWS GENETICS (2019)

Add to Collection

Review Oncology

Tumour heterogeneity and resistance to cancer therapies

Ibiayi Dagogo-Jack et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times

Somak Roy et al.

GASTROENTEROLOGY (2018)

Add to Collection

Article Pathology

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Guido Rindi et al.

MODERN PATHOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup

Chang S. Chan et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Correction Multidisciplinary Sciences

Whole-genome landscape of pancreatic neuroendocrine tumours (vol 543, pg 65, 2017)

Aldo Scarpa et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

Whole-genome landscape of pancreatic neuroendocrine tumours

Aldo Scarpa et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors

Thomas Januario et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Add to Collection

Article Cell Biology

Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2

Lian Dee Ler et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Article Cell Biology

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

Teresa Ezponda et al.

CELL REPORTS (2017)

Add to Collection

Article Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari et al.

JAMA ONCOLOGY (2017)

Add to Collection

Review Oncology

EMT, cell plasticity and metastasis

Christine L. Chaffer et al.

CANCER AND METASTASIS REVIEWS (2016)

Add to Collection

Review Oncology

DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications

Iris H. Liu et al.

CANCER TREATMENT REVIEWS (2016)

Add to Collection

Article Endocrinology & Metabolism

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

M. Pavel et al.

NEUROENDOCRINOLOGY (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Benjamin G. Bitler et al.

NATURE MEDICINE (2015)

Add to Collection

Article Gastroenterology & Hepatology

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

P. Dieckhoff et al.

DIGESTION (2014)

Add to Collection

Article Surgery

Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors An Analysis of the AJCC and ENETS Staging Classifications

Jonathan R. Strosberg et al.

ANNALS OF SURGERY (2012)

Add to Collection

Article Multidisciplinary Sciences

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

Yuchen Jiao et al.

SCIENCE (2011)

Add to Collection

Article Oncology

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

Edoardo Missiaglia et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.